Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Pharma Pulse 11/19/24: Is Any Data Better Than No Data? Exploring Emerging Vitiligo Therapies & more
Pharmaceutical Executive November 19, 2024
The latest news for pharma industry insiders.
Are Any Data in Clinical Trials Better than No Data At All?
The answer comes down to context of use—and knowing the motives for “missingness.”
Exploring Emerging Therapies in Vitiligo
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
Makers of Ozempic, Zepbound fight to stop compounded copies of their drugs; unclear whether pharmaceutical companies can increase production enough.
Hims & Hers Appoints Tenured...
Today's Sponsors
Today's Sponsor